Literature DB >> 21643034

Ulcerative colitis: Rescue immune suppression for severe colitis--worth the risk?

Giovanni C Actis, Marco Daperno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21643034     DOI： 10.1038/nrgastro.2011.86

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.

Authors:  W A Faubion; E V Loftus; W S Harmsen; A R Zinsmeister; W J Sandborn
Journal:  Gastroenterology       Date:  2001-08       Impact factor: 22.682

2.  Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.

Authors:  A Gustavsson; G Järnerot; E Hertervig; I Friis-Liby; L Blomquist; P Karlén; C Grännö; M Vilien; M Ström; H Verbaan; P M Hellström; A Magnuson; J Halfvarson; C Tysk
Journal:  Aliment Pharmacol Ther       Date:  2010-08-18       Impact factor: 8.171

3.  Cyclosporine is safe and effective in patients with severe ulcerative colitis.

Authors:  Adam S Cheifetz; Joshua Stern; Sagar Garud; Eric Goldstein; Lisa Malter; Alan C Moss; Daniel H Present
Journal:  J Clin Gastroenterol       Date:  2011-02       Impact factor: 3.062

4.  Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients.

Authors:  Willem E Hueting; Erik Buskens; Ingeborg van der Tweel; Hein G Gooszen; Cees J H M van Laarhoven
Journal:  Dig Surg       Date:  2005-04-14       Impact factor: 2.588

5.  Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis.

Authors:  S Leblanc; M Allez; P Seksik; B Flourié; H Peeters; J L Dupas; G Bouguen; L Peyrin-Biroulet; B Duclos; A Bourreille; O Dewit; Y Bouhnik; P Michetti; S Chaussade; P Saussure; J Y Mary; J F Colombel; M Lémann
Journal:  Am J Gastroenterol       Date:  2011-03-08       Impact factor: 10.864

6.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Authors:  Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Donny M Chen; Michelle L Pritchard; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05       Impact factor: 11.382

7.  Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.

Authors:  Elana A Maser; Deepthi Deconda; Simon Lichtiger; Thomas Ullman; Daniel H Present; Asher Kornbluth
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10       Impact factor: 11.382

8.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

Authors:  I Arijs; K Li; G Toedter; R Quintens; L Van Lommel; K Van Steen; P Leemans; G De Hertogh; K Lemaire; M Ferrante; F Schnitzler; L Thorrez; K Ma; X-Y R Song; C Marano; G Van Assche; S Vermeire; K Geboes; F Schuit; F Baribaud; P Rutgeerts
Journal:  Gut       Date:  2009-08-20       Impact factor: 23.059

9.  Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis.

Authors:  Joris Arts; Geert D'Haens; Miranda Zeegers; Gert Van Assche; Martin Hiele; André D'Hoore; Freddy Penninckx; Severine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-03       Impact factor: 5.325

10.  Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study.

Authors:  Giovanni C Actis; Maurizio Fadda; Ezio David; Anna Sapino
Journal:  BMC Gastroenterol       Date:  2007-03-27       Impact factor: 3.067
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.